FDA approves Eli Lilly's sarcoma drug

Indianapolis-based drugmaker Eli Lilly earned accelerated approval from the Food and Drug Administration for a drug to treat adults with advanced soft tissue sarcoma, reports Reuters.

The FDA's Accelerated Approval Program allows for the earlier approval of drugs to fill an unmet clinical need, according to the agency's website.

The agency approved the drug, Lartruvo, for combined use with the chemotherapy agent doxorubicin in soft tissue sarcoma patients who cannot be cured with radiation or surgery, according to the report.

Lartruvo earned orphan drug status and breakthrough therapy status — designations intended to expedite the development and review of promising new drugs — from the FDA prior to winning accelerated approval.

More articles on supply chain:

FDA OKs Roche's Tecentriq for lung cancer patients
Texas Medical Center partners with J&J to develop medical devices
Prescription drug costs see largest jump in 24 years

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months